Prescription of Aspirin for adults with Diabetes
- PMID: 19902048
- PMCID: PMC2772009
- DOI: 10.4103/0973-3930.43099
Prescription of Aspirin for adults with Diabetes
Abstract
Background: To evaluate the prescription of aspirin for primary and secondary prevention of cardiovascular disorders in diabetic patients, in the light of American Diabetes Association guidelines.
Materials and methods: In this retrospective analysis, presence of any cardiovascular disease or cardiovascular disease risk factor as defined in American Diabetes Association guidelines and the use of aspirin and other medication data were extracted from the case files of 100 patients with type 2 diabetes mellitus visiting two teaching hospitals.
Results: Of 100 patients studied, 58% were men and 42% women and all were >/= 40 years of age. 45% had at least one cardiovascular disease and all (100%) were on aspirin for secondary prevention; 45% had one or more risk factors, of which 11% (05/45) had aspirin prescribed for primary prevention; remaining 10% had neither risk factors nor cardiovascular disease (but age >/= 40 years) and no aspirin documentation. Reasons for not using aspirin/antiplatelet drug were not recorded.
Conclusions: American Diabetes Association recommendations for aspirin use for secondary prevention of cardiovascular diseases were strictly adhered to, in contrast to that for primary prevention. Under-prescription of aspirin could be attributed to the physicians' concern about the burden of poly-pharmacy and toxic effects of aspirin on long-term use. Extensive efforts are necessary to enhance aspirin use in this regard.
Keywords: Aspirin; cardio-vascular disease; diabetes mellitus..
Conflict of interest statement
Similar articles
-
Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6. doi: 10.1016/j.numecd.2004.04.001. Nutr Metab Cardiovasc Dis. 2005. PMID: 15871850
-
[Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel].Harefuah. 2008 Dec;147(12):971-4, 1030. Harefuah. 2008. PMID: 19260592 Hebrew.
-
Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.Thromb Res. 2007;121(1):43-50. doi: 10.1016/j.thromres.2007.03.006. Epub 2007 Apr 25. Thromb Res. 2007. PMID: 17462716
-
Update on aspirin in the treatment and prevention of cardiovascular disease.Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Am J Manag Care. 2002. PMID: 12512736 Review.
-
Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus.Am J Cardiovasc Drugs. 2004;4(2):87-106. doi: 10.2165/00129784-200404020-00003. Am J Cardiovasc Drugs. 2004. PMID: 15049721 Review.
References
-
- Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and non diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. - PubMed
-
- Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow up. Arch Intern Med. 2001;161:1717–23. - PubMed
-
- American Diabetes Association. Aspirin therapy in diabetes (Position Statement) Diabetes Care. 2004;27:S72–3. - PubMed
-
- Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes. Diabetes Care. 2001;24:197–201. - PubMed
-
- Wood DM, Plehwe WE, Colman PG. Aspirin usage in a large teaching hospital diabetic setting. Diabet Med. 1999;16:605–8. - PubMed
LinkOut - more resources
Full Text Sources